NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3 | -62.5% | 3,100 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $8 | -33.3% | 3,100 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $12 | +20.0% | 3,100 | +47.6% | 0.00% | 0.0% |
| Q4 2022 | $10 | -99.9% | 2,100 | -30.0% | 0.00% | 0.0% |
| Q3 2022 | $19,000 | +1800.0% | 3,000 | +500.0% | 0.00% | – |
| Q2 2022 | $1,000 | -66.7% | 500 | -88.6% | 0.00% | – |
| Q1 2022 | $3,000 | -78.6% | 4,400 | -78.1% | 0.00% | -100.0% |
| Q4 2021 | $14,000 | -62.2% | 20,100 | +200.0% | 0.00% | -50.0% |
| Q3 2021 | $37,000 | +94.7% | 6,700 | +509.1% | 0.00% | +100.0% |
| Q2 2021 | $19,000 | -68.9% | 1,100 | -47.6% | 0.00% | -66.7% |
| Q1 2021 | $61,000 | +1.7% | 2,100 | +5.0% | 0.00% | 0.0% |
| Q4 2020 | $60,000 | +900.0% | 2,000 | +100.0% | 0.00% | – |
| Q3 2020 | $6,000 | -33.3% | 1,000 | -9.1% | 0.00% | – |
| Q2 2020 | $9,000 | – | 1,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |